Prima BioMed (PBMD) is an Australian-listed Biotech company which is cross-listed on the NASDAQ with an ADR. Given its international listing, its market cap ($125m), and, its liquidity (22k shares average, or $70k notional traded daily), it has received little exposure despite a compelling technology platform, solid cash position, and upcoming data catalysts. As management has gotten on the road and started to tell the story, the stock has responded somewhat (from $2.50 in mid-July to $3.20 at 7/30 close), but given the low volumes and overall outlook, I believe there is still room left to run…with some caveats that I will discuss later.
First, some brief background. Prima styles itself as a leader in developing personalized...
Only subscribers can access this article, which is part of the PRO research library covering 3,600 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: